{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:45:43Z","timestamp":1751363143549},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.parkreldis.2015.01.002","type":"journal-article","created":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T02:06:16Z","timestamp":1420855576000},"page":"340-342","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rasagiline for the treatment of parkinsonism in Huntington's disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Jes\u00fas","family":"P\u00e9rez-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u00fcl","family":"Mart\u00ednez-Horta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pagonabarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Carceller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2015.01.002_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2015.01.002_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of Huntington's disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2015.01.002_bib3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJM198005083021916","article-title":"Levodopa and presymptomatic detection of Huntington's disease\u2013eight-year follow-up","volume":"302","author":"Klawans","year":"1980","journal-title":"NEMJ"},{"key":"10.1016\/j.parkreldis.2015.01.002_bib4","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/WNL.54.9.1753","article-title":"Decreased striatal monoaminergic terminals in Huntington disease","volume":"54","author":"Bohnen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2015.01.002_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease","volume":"61","year":"2004","journal-title":"Arch Neurol"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T11:22:12Z","timestamp":1537960932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802015000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1353802015000061"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.01.002","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rasagiline for the treatment of parkinsonism in Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}